Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (720)

« Back to Publications

Mitigating health inequities with machine learning: a nationwide cohort study developing and evaluating ethnicity-specific cardiovascular risk prediction models across 19 ethnically diverse populations in 2.5 million individuals with COVID-19

Allery F. et al, (2026), Lancet Digital Health

Going beyond cycling versus swapping for treatment sequencing in psoriatic arthritis.

Lema Martinez JM. and Coates LC., (2026), Nat Rev Rheumatol

Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomized, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial

Coates L., (2026), Annals of the Rheumatic Diseases

Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF : post hoc analysis of SELECT-PsA 2

Coates L., (2026), RMD Open

Immunometabolic mechanisms across psoriatic disease: Linking psoriasis to psoriatic arthritis

Coates L. et al, (2026), Clinical Rheumatology

Psoriatic Arthritis and Obesity: A Review of Clinical Burden and Considerations for Comprehensive Care

Coates L., (2026), RMD Open

TaILOR: a randomised trial to compare the clinical and cost-effectiveness of a patient-initiated follow-up (PIFU) strategy compared to standard care pathways in people with inflammatory arthritis: a study protocol.

Brewer G. et al, (2026), Trials, 27

Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST

Coates LC. et al, (2026), Rheumatology

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

Coates LC. et al, (2026), RMD Open, 20, e043855 - e043855

Effects of Guselkumab on Structural Damage Progression in Patients with Active Psoriatic Arthritis

Ritchlin CT. et al, (2026), Advances in Therapy

Control of Inflammation and Sustained Improvements in Patient‐Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two‐Year Results From Two Phase 3 Studies

Gossec L. et al, (2026), ACR Open Rheumatology, 8

Celebrating 50 years of spondyloarthritis

Helliwell PS. et al, (2026), EULAR Rheumatology Open, 100197 - 100197

State of the art and novel treatments in psoriatic arthritis.

Hackett S. et al, (2026), Best Pract Res Clin Rheumatol

Further Validation of a Questionnaire to Assess Flare in Psoriatic Arthritis: Determination of Cutoff and Longitudinal Change.

Helliwell PS. et al, (2026), J Rheumatol

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.

Merola JF. et al, (2026), Arthritis Rheumatol

Load More

1
2
3
4
5
6
7
...
»